ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Two-year efficacy and safety outcomes of the Paul Glaucoma Implant compared to the Ahmed Glaucoma Valve.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare efficacy and safety profiles of the Paul Glaucoma Implant (PGI) and Ahmed Glaucoma Valve (AGV) in the treatment of adults with glaucoma over a 2-year of follow-up period.
methodsThis retrospective, single-center, comparative study included adult patients who underwent standalone PGI or AGV surgery at the University Medical Center Mainz. Twenty-two consecutive patients treated with the PGI were compared with a historical cohort of 17 eyes that underwent AGV implantation prior to the introduction of the PGI, all with a minimum follow-up of 24 months. The primary outcome measures were changes in intraocular pressure (IOP) and the number of antiglaucoma medications at two years postoperatively. Secondary outcome measures included complete and qualified success rates, failure rates, best-corrected visual acuity (logMAR), and the incidence of adverse events.
resultsAt 24 months of follow-up, median intraocular pressure (IOP) decreased similarly in both groups, from 28.0 mmHg (IQR 16) to 12.0 mmHg (IQR 9) in the AGV group and from 32.5 mmHg (IQR 11) to 14.0 mmHg (IQR 4) in the PGI group. Overall qualified success rates were comparable between groups for target IOP criteria of ≤ 21 mmHg with ≥ 25% reduction and ≤ 15 mmHg with ≥ 40% reduction. However, the PGI group demonstrated higher success rates for the target IOP of ≤ 18 mmHg with ≥ 30% reduction. The AGV group exhibited a higher incidence of early postoperative complications and bleb encapsulation.
conclusionBoth PGI and AGV were safe and effective in reducing intraocular pressure over 2 years. PGI was associated with lower device obstruction rates and a higher likelihood of achieving an intraocular pressure of ≤ 18 mmHg at 2 years.
Indexed as
Identifiers
42566004What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.